Q The idea of regulating the media is very much in the news. What are your views on the matter? A Obviously, the ideal way to do this would be self-regulation. I don’t think anyone in the profession has any doubt about that. Everybody agrees that self-regulation is a very good thing, but we don’t seem to move beyond that. And we are consequently opening a window for people who want...

A classroom reflecting life's diversity will benefit children of all strata while enriching teaching experience. Now that the Supreme Court has validated the Right to Education (RTE), its success will depend on teachers. When I said this to a friend who teaches in a primary school, she said, “you are being unfair.” I was startled to hear this response because what I had said was common sense. When I pointed this...

Industry reacts with caution to the grant of a compulsory licence to Natco, but cancer patients welcome it and hope for many more. THE first compulsory licence (CL) issued by the Indian patent office, to the local drug manufacturer Natco Pharma Ltd to sell the generic version of Bayer AG's anti-cancer drug Nexavar, has led to varied reactions. The landmark decision has also raised concerns about the outcome of cases...

India's efforts to produce and supply life-saving drugs at affordable prices face challenges from multinational companies trying to “evergreen” their patents. THE average life expectancy across the globe has increased from around 30 years a century ago to over 65 years today. This has been made possible in large part by modern medicine. Never before in history have humans had access to such an array of medicines and devices to...

India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines. AS was only to be expected, the two landmark decisions made by the Indian patent office in recent times concerning pharmaceutical patent cases have not gone down well with the multinational drug industry. First, there was the rejection in 2006 of the patent application by the Swiss multinational...